asco gu23 checkmate-9er biomarker analysis: toni choueiri, md | dana-farber cancer institute
Published 1 year ago • 84 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:22
asco gu23 toni choueiri, md: checkmate-9er 3-year follow-up | dana-farber cancer institute
-
2:12
asco23: toni choueiri, md | dana-farber cancer institute
-
1:01
asco gu23 toni choueiri, md: keynote-564 subgroup analysis | dana-farber cancer institute
-
1:19
asco gu23 triplet therapy in kidney cancer: toni choueiri, md | dana-farber cancer institute
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
5:41
02 how to take a grab sample 2 original
-
3:41
a physician faces stage iv #kidneycancer: his advice for you
-
3:35
checkmate-9er discussion: depth of response with first-line cabozantinib/nivolumab
-
2:31
asco gu 2019 - dr. toni choueiri, dana-farber cancer institute, usa
-
2:41
living with kidney cancer | dana-farber cancer institute
-
1:08
kidney cancer expert dr. toni choueiri: the 2022 kidney cancer research summit by kidneycan
-
3:12
researcher comment: the fraction-rcc study | toni choueiri
-
1:49
cosmic-313: cabozantinib with nivolumab and ipilimumab in untreated arcc
-
16:16
2022 gu asco kidney cancer highlights
-
5:21
jorge a. garcia, md, summarizes the significance of checkmate 9er from asco gu 2021
-
0:59
genitourinary cancer updates at asco 2023
-
26:17
2022 gu asco bladder cancer highlights
-
6:50
esmo 2022: renal roundup